%20-%20w015.jpg?width=1200&height=675&name=04_Featured_Live_Image%20(1200%C3%97675)%20-%20w015.jpg "04_Featured_Live_Image (1200×675) - w015")
Addressing Genotoxic Liabilities in Drug Development: Follow-up Testing Strategies to Manage Risk
Genetic toxicology is a critical endpoint in drug development because genotoxic findings can alter development strategy, trigger additional testing, or stop a program altogether. The real challenge is not just detecting a liability, but determining what it means, whether it is relevant in vivo, and what follow-up strategy provides the clearest path forward.
This webinar is an encore presentation of Scantox’s Exhibitor Hosted Session presented at the 65th Annual Meeting of the Society of Toxicology in March 2026 in San Diego: “Addressing Genotoxic Liabilities in Drug Development: Follow-up Testing Strategies to Manage Risk.”
Join Matt Tate, PhD, Chief Business Development Officer at Scantox, on April 14, 2026 | 15:00 CEST (09:00 AM EDT), followed by a live Q&A session.
This session will examine how to build and defend a practical follow-up strategy when genotoxic signals emerge in screening or development. Topics will include the Genotox Triangle of mutagenicity, clastogenicity, and aneugenicity; interpretation of Ames-positive findings; mechanism-informed follow-up study design; and the use of assays such as Comet, MLA, HPRT, in vivo micronucleus with FISH/CREST, GLP OECD 488 Big Blue®, and DuplexSeq™ within a modern genetic toxicology strategy.
Key Learning Objectives
- Understand the three core genotoxic liability types: mutagenicity, clastogenicity, and aneugenicity.
- Learn how to interpret Ames-positive findings and define appropriate follow-up paths.
- See how mechanism of action informs assay selection and in vivo study design.
- Review practical follow-up options including Comet, MLA, HPRT, micronucleus, TGR/Big Blue®, and DuplexSeq™.
- Understand how to build a more coherent, regulator-aware genotoxicity strategy across screening and development.
Who Should Attend
- Nonclinical safety & toxicology leads responsible for genotox strategy and regulatory packages.
- Discovery and development scientists managing compounds with emerging genotoxic liabilities.
- CMC, analytical, and impurity teams evaluating mutagenic risk and follow-up needs.
- Regulatory affairs and project leaders supporting progression to clinical development.
- Outsourcing managers and scientific consultants seeking integrated genetic toxicology support.
Meet The Presenter
Matt Tate, PhD, is Chief Business Development Officer at Scantox and a recognized expert in genetic toxicology with more than 20 years of experience in the field. Over the course of his career, he has helped shape genetic toxicology strategy across screening, regulatory follow-up, and broader nonclinical safety assessment, with particular depth in assay selection, interpretation of mutagenicity findings, and sponsor guidance on practical risk-management pathways.
Matt previously played a central role in the growth of Gentronix as a leading predictive and genetic toxicology organization and continues to work at the intersection of scientific rigor, commercial strategy, and client-facing problem solving at Scantox. He holds a BSc in Biochemistry from the University of Leeds and a PhD in Genetic Toxicology from the University of Manchester.